Factors associated with relapse after discontinuation of long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B

Abstract

Abstract: Nucleos(t)ide-analogues(NAs) is widely applied to the antiviral therapy of hepatitis B virus (HBV)clinically.However, few patients treated with NAs could reach HBsAg clearance, considering the ideal end-point of treatment. Over the past decades, researchers have increasingly focused on optimal stopping strategies, mainly in which indicators could effectively predict clinical outcomes and during which optimal time point to perform. The report summarizes the crucial factors causing the relapse after the NAs treatment is stopped based on virology and host immunology：①Serum HBsAg, HBcrAg, and HBV RNA play crucial roles in determining end-point of NAs’antiviral therapy.②Immunological factors including levels of cytokines, natural immune responses and adaptive immune responses. In addition, NK cell and HBV-specific T cell are closely associated with host immune response.③The interaction between virological and immunological factors induce the clinical outcomes.

Key words: Chronic hepatitis B, nucleos(t)ide-analogues, relapse, immune response

DING Xia, LIAO Gui-chan, XIA Mu-ye, PENG Jie. Factors associated with relapse after discontinuation of long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B[J]. Electronic Journal of Emerging Infectious Diseases, 2019, 4(1): 52-57.

References

[1] Stanaway JD, Flaxman AD, Naghavi M, et al.The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013[J]. Lancet, 2016, 388(10049): 1081-1088.
[2] Lozano RP, Naghavi MP, Foreman KM, et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128.
[3] Ruan P, Xu SY, Zhou BP, et al.Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: A clinical study[J]. J Int Med Res, 2013, 41(5): 1732-1739.
[4] Seto W, Hui A J, Wong V W, et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study[J]. Gut, 2015, 64(4): 667-672.
[5] Chen C H, Hsu Y C, Lu S N, et al.The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients[J]. J Viral Hepat, 2018, 25(5): 590-597.
[6] Wang C, Tseng K, Hsieh T, et al.Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg[J]. Am J Gastroenterol, 2016, 111(9): 1286-1294.
[7] Wang J, Shen T, Huang X, et al.Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. JJ Hepatol, 2016, 65(4): 700-710.
[8] Wang J, Du M, Huang H, et al.Consistent loss of serum HBV RNA might predict the “para-functional cure” of chronic hepatitis B[J]. J Hepatol, 2016, 66(2): 462-463.
[9] Wang Jing, Yu Yiqi, Li Guojun, et al.Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J]. J Hepatol, 2017, 8278(17): 32261-32264.
[10] Akinori Rokuhara, Akihiro Matsumoto, Eiji Tanaka, et al.Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy[J]. J Gastroenterol, 2006, 41(8): 785-790.
[11] Yoon S K, Jang J W, Kim C W, et al.Long-Term Results of Lamivudine Monotherapy in Korean Patients with HBeAg-Positive Chronic Hepatitis B: Response and Relapse Rates, and Factors Related to Durability of HBeAg Seroconversion[J]. Intervirology, 2005, 48(6): 341-349.
[12] Ryu DK, Ahn Y, Ryu WS, et al.Development of a novel hepatitis B virus encapsidation detection assay by viral nucleocapsid-captured quantitative RT-PCR[J]. Biotechniques, 2015, 59(5): 287-293.
[13] Kimura T, Ohno N, Terada N, et al.Hepatitis B Virus DNA-negative Dane Particles Lack Core Protein but Contain a 22-kDa Precore Protein without C-terminal Arginine-rich Domain[J]. J Biol Chem, 2005, 280(23): 21713-21719.
[14] Wang B, Carey I, Bruce M, et al.HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues[J]. J Viral Hepat, 2018, 25(8): 886-893.
[15] Shinkai N, Tanaka Y, Orito E, et al.Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection[J]. Hepatol Res, 2006, 36(4): 272-276.
[16] Matsumoto A, Tanaka E, Minami M, et al.Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy[J]. Hepatol Res, 2007, 37(8): 661-666.
[17] Boni CLDLP.Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues[J]. Gastroenterology, 2012, 143(4): 963-973.
[18] Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al.Discontinuation of oral antivirals in chronic hepatitis B: A systematic review[J]. Hepatol Res, 2016, 63(5): 1481-1492.
[19] Siederdissen C, Rinker F, Maasoumy B, et al.Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B[J]. J Infect Dis, 2016, 214(10): 1492-1497.
[20] Christine L. Zimmer FRCH.Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss[J]. J Infect Dis, 2018, 217(10):1656-1666.
[21] Caligiuri M A.Human natural killer cells[J]. Blood, 2008, 112(3): 461-469.
[22] Vivier E, Tomasello E, Baratin M, et al.Functions of natural killer cells[J]. Nature Immunology, 2008, 9(5): 503-510.
[23] Rinker FZCHZ: Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B[J]. J Hepatol, 2018, 69(3): 584-593.
[24] Rivino L LBNG: Hepatitis B virus-specific Tcells 2018 JCI[J]. J Clin Invest, 2018, 128(2): 668-681.